Fall in global markets and profit booking after gain in previous two sessions weighed on the Indian equity benchmarks. Major Asian markets like Shanghai, Hang Seng and Nikkei were down 1.5-2%. Straits Times, Kospi and Taiwan fell 0.5-1%. US equity markets had fallen more than 2% yesterday after disappointing manufacturing data and Moody's downgraded Greece ratings by three notches.


HUL was the leading stock on Nifty, with rising over 3%. ITC, NTPC, SAIL, Sun Pharma, Bajaj Auto and Cipla were other leading counters, with gaining 1-2%. Heavyweights SBI, ONGC, Reliance Industries and Bharti Airtel were marginally in the green.

महंगे तेल,ब्याज से बिक्री पर दबाव

मारुति सुजुकी के चीफ जनरल मैनेजर के मुताबिक तेल की कीमतें चढ़ने और ब्याज दरों में बढ़त के असर से बिक्री में अनुमान से कम बढ़त हुई है।

छोटी कारें लेने वाले ज्यादातर ग्राहक कार लोन लेकर ही कारें खरीदते हैं। ब्याज दरें बढ़ने के असर से कंपनी की छोटी कारों (ए2 सेगमेंट) की बिक्री घटी है। मारुति सुजुकी की कुल बिक्री का 65 फीसदी ए2 सेगमेंट से आता है।

ए3 सेगमेंट की आय बढ़ रही है। मारुति की डीजल कारें मारुति डिजायर और एसएक्स4 इसी श्रेणी की कारें हैं। शशांक श्रीवास्तव के मुताबिक अगर सरकार डीजल को नियंत्रण मुक्त करती है और जिससे डीजल की कीमतें बढ़ेंगी तो कंपनी को भी नुकसान हो सकता है।

Nifty Close below 5600

Indian equity benchmarks continued their uptrend for second consecutive session on Wednesday. The 50-share NSE Nifty closed tad below the 5600 mark - it tried to cross that level during the day but could not make it.
The index settled at 5,592, up 31.85 points and the 30-share BSE Sensex gained 105.53 points, to end at 18,608.81. Indices were highly volatile in an intraday trade, with a positive bias. Market breadth too was in favour of advances - two shares gained as against every one share declined.

In US Sun Pharma scouts for sizeable target

The inorganic growth strategy of Sun Pharma is driven by a rising health spend in US and other emerging markets. According to the US-based IMS Institute, global health spend is expected to touch $ 1.1 trillion mark by 2015, growing at 3-6% per annum.

“Globally, market share for branded medicines, which fell from 70% in 2005 to 64% in 2010, is expected to decline further through 2015, to 53%,” the IMS analysis said. This means 47% of the total drugs sold in 2015 would be generics or off-patent versions of the original drug.

No wonder then, Sun Pharmaceutical, a generics player, is excited about the opportunity in the US. The ageing population in the developed markets is expected to drive incremental spending on drugs, both branded and generics.

Nifty choppy

Equity benchmarks gained further amid a choppy trade - the Nifty was inching towards the 5600 level - supported majorly by power, capital goods, metal, technology, cement and telecom companies' shares. Anil Dhirubhai Ambani Group (ADAG) stocks too were on buyers' radar at 10:35 hours.

The 30-share BSE Sensex was trading at 18,602, up 98 points and the 50-share NSE Nifty rose 27 points to 5,587. The broader indices were outperforming benchmarks - the BSE Midcap Index was up 0.8% and Smallcap up 1%.